A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Mark
κ-opioid receptor - Wikipedia
PDF) Purification of a kappa-opioid receptor subtype from frog brain | Mária Szücs, Anna Borsodi, and Kálmán Medzihradszky - Academia.edu
Articles with Cara Therapeutics, Inc. | page 5
PDF) Effect of Difelikefalin, a Selective Kappa Opioid Receptor Agonist, on Respiratory Depression: A Randomized, Double‐Blind, Placebo‐Controlled Trial
PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users
Molecules | Free Full-Text | Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects
Difelikefalin: First Approval
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus | NEJM
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
A New Path to Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)Friday, March 17, 201712:30 PM – 1:30 PMGrand Caribbean Ballroom 7Loews Sapphire Falls ResortOrlando, Florida Survey
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink